Swiss National Bank Makes New Investment in Savara Inc. $SVRA

Swiss National Bank bought a new position in shares of Savara Inc. (NASDAQ:SVRA) during the 1st quarter, Holdings Channel.com reports. The fund bought 136,800 shares of the company’s stock, valued at approximately $747,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Principal Financial Group Inc. bought a new stake in shares of Savara in the first quarter valued at approximately $57,000. Fifth Third Bancorp bought a new position in Savara during the 1st quarter worth $363,000. Pictet Asset Management Holding SA bought a new position in Savara during the 1st quarter worth $12,424,000. SG Americas Securities LLC increased its stake in Savara by 26.1% during the 1st quarter. SG Americas Securities LLC now owns 57,400 shares of the company’s stock worth $313,000 after acquiring an additional 11,874 shares during the period. Finally, Caitong International Asset Management Co. Ltd raised its holdings in Savara by 1,887.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 39,649 shares of the company’s stock valued at $239,000 after acquiring an additional 37,654 shares in the last quarter. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have recently weighed in on SVRA. Oppenheimer initiated coverage on Savara in a research report on Friday, April 24th. They set an “outperform” rating and a $11.00 target price for the company. Wall Street Zen upgraded Savara from a “sell” rating to a “hold” rating in a research report on Saturday, June 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Savara in a research note on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Savara presently has an average rating of “Moderate Buy” and an average target price of $10.14.

Savara Stock Performance

NASDAQ:SVRA opened at $5.46 on Friday. The stock’s 50-day simple moving average is $5.58 and its 200 day simple moving average is $5.51. The firm has a market capitalization of $1.12 billion, a PE ratio of -9.75 and a beta of 0.24. The company has a quick ratio of 13.47, a current ratio of 13.47 and a debt-to-equity ratio of 0.17. Savara Inc. has a twelve month low of $2.43 and a twelve month high of $7.01.

Savara (NASDAQ:SVRA) last released its earnings results on Tuesday, May 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). On average, analysts anticipate that Savara Inc. will post -0.57 EPS for the current fiscal year.

About Savara

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.